Biological characterization of TAS3681, a new type of androgen receptor antagonist with androgen receptor downregulating activity

被引：0
|
作者：
Minamiguchi, K. [1 ]
Seki, M. [1 ]
Aoyagi, H. [1 ]
Mori, T. [1 ]
Kajiwara, D. [1 ]
Masuko, N. [1 ]
Fujita, R. [1 ]
Okajima, S. [1 ]
Hayashi, Y. [1 ]
Sasaki, E. [1 ]
Utsugi, T. [1 ]
机构：
[1] Taiho Pharmaceut Co Ltd, Tsukuba Res Ctr, Ibaraki, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)70441-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
315
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [1] TAS3681: New class of androgen receptor antagonist with androgen receptor downregulating activity.
    Minamiguchi, Kazuhisa
    Seki, Masanao
    Aoyagi, Hiroki
    Kajiwara, Daisuke
    Mori, Tomoko
    Masuko, Norio
    Fujita, Ryouto
    Okajima, Shigeo
    Hayashi, Yukio
    Sasaki, Eiji
    Utsugi, Teruhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [2] TAS3681, an androgen receptor antagonist, prevents drug resistance driven by aberrant androgen receptor signaling in prostate cancer
    Yoshida, Shohei
    Kajiwara, Daisuke
    Seki, Masanao
    Tayama, Manabu
    Tanaka, Yuki
    Mizutani, Hiroya
    Fujita, Ryoto
    Yamamura, Keisuke
    Okajima, Shigeo
    Asai, Masanori
    Minamiguchi, Kazuhisa
    MOLECULAR ONCOLOGY, 2024, 18 (08) : 1980 - 2000
  • [3] Effect of a new type androgen receptor antagonist, TAS3681, on ligand-independent AR activation through its AR downregulation activity.
    Kajiwara, Daisuke
    Minamiguchi, Kazuhisa
    Seki, Masanao
    Mizutani, Hiroya
    Aoyagi, Hiroki
    Okajima, Shigeo
    Sasaki, Eiji
    Utsugi, Teruhiro
    Iwasawa, Yoshikazu
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [4] TAS3681, a new type of androgen receptor antagonist, disrupts aberrant AR signaling that drives tumor resistance to AR-targeted therapies by downregulating full-length and splice variant AR
    Kajiwara, D.
    Minamiguchi, K.
    Seki, M.
    Mizutani, H.
    Yamamura, K.
    Okajima, S.
    Sasaki, E.
    Utsugi, T.
    Iwasawa, Y.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S127 - S127
  • [5] TAS3681, a novel type of AR antagonist with AR downregulating activity, as a new targeted therapy for aberrant AR-driven prostate cancer.
    Seki, Masanao
    Minamiguchi, Kazuhisa
    Kajiwara, Daisuke
    Mizutani, Hiroya
    Yoshida, Shohei
    Sasaki, Eiji
    Utsugi, Teruhiro
    Iwasawa, Yoshikazu
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [6] The impact of TAS3681, a new type of androgen receptor antagonist, on aberrant AR signaling that drives tumor resistance to AR-targeted therapies by down-regulating full length and splice variant AR.
    Kajiwara, Daisuke
    Minamiguchi, Kazuhisa
    Seki, Masanao
    Mizutani, Hiroya
    Yamamura, Keisuke
    Okajima, Shigeo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [7] Peptide Antagonist of the Androgen Receptor
    Gao, Wenqing
    CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (09) : 1106 - 1113
  • [8] A chemoenzymatic synthesis of an androgen receptor antagonist
    Vaidyanathan, Rajappa
    Hesmondhalgh, Lynsey
    Hu, Shanghui
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2007, 11 (05) : 903 - 906
  • [9] THE ANDROGEN RECEPTOR - NEW INSIGHTS INTO ANDROGEN INSENSITIVITY
    EBERLE, J
    KLOCKER, H
    UROLOGE A, 1993, 32 (06): : 460 - 465
  • [10] Androgen Receptor Rediscovered: The New Biology and Targeting the Androgen Receptor Therapeutically
    Ryan, Charles J.
    Tindall, Donald J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27) : 3651 - 3658
12345